国产精品99精品无码视亚,小荡货腿张开让我cao爽视频,精品无码一区二区三区av,人人妻人人添人人爽日韩欧美

Toggle Nav
新聞發(fā)布 | Medix Biochemica收購Diaclone以擴(kuò)充其單克隆抗體產(chǎn)品線

Press release_Diaclone.jpg

? Medix Biochemica收購了Diaclone全部股份，Diaclone以其炎癥、腫瘤、及免疫學(xué)等相關(guān)領(lǐng)域的單克隆抗體而享有盛譽(yù)。

Medix Biochemica has acquired 100 percent of the shares of Diaclone, a prominent provider of monoclonal antibodies in the areas of inflammation, oncology and immunology.


? 本次并購使Medix Biochemica全球領(lǐng)先的體外診斷原料產(chǎn)品線得到進(jìn)一步擴(kuò)充，并引入了互補(bǔ)的產(chǎn)品研發(fā)能力、加強(qiáng)了公司在西歐的力量。

The acquisition expands Medix Biochemica's leading portfolio of IVD raw materials, bringing complementary scientific and technological capabilities and strengthening the company's local presence in Western Europe.


? 通過此次并購，IVD客戶將得以通過Medix Biochemica的全球銷售網(wǎng)絡(luò)輕松獲取Diaclone的任意產(chǎn)品。

As a result of the transaction, Diaclone's product portfolio will be available through Medix Biochemica's comprehensive global sales network.

全球領(lǐng)先的IVD關(guān)鍵原料供應(yīng)商Medix Biochemica從Biotech Investissement集團(tuán)獲得Diaclone SAS (以下簡稱"Diaclone")的全部股權(quán)。本次并購讓Medix Biochemica全球領(lǐng)先的體外診斷關(guān)鍵原料產(chǎn)品線得到了進(jìn)一步擴(kuò)充，并引入了互補(bǔ)的科技能力、加強(qiáng)了公司在西歐的力量。Diaclone將成為Medix Biochemica集團(tuán)免疫診斷試劑原料業(yè)務(wù)單元的重要組成部分，其高質(zhì)量的運(yùn)營將繼續(xù)保留在法國貝桑松。

Medix Biochemica, a global leader in critical IVD raw materials, has acquired 100 percent of the shares of Diaclone SAS ("Diaclone") from Biotech Investissement Group. As a result of the acquisition, Medix Biochemica broadens its portfolio of critical raw materials for the in vitro diagnostics ("IVD") industry, complements its scientific expertise and strengthens its local presence in Western Europe. Diaclone will become an important part of the Immunodiagnostic Reagents Business Unit within Medix Biochemica's group structure, and its high-quality operations will continue in Besan?on, France. 


Diaclone成立于1986年，因其在炎癥、腫瘤、及免疫學(xué)等領(lǐng)域的專長而知名。公司提供一流的單克隆抗體、高品質(zhì)的ELISA及ELISpot試劑；同時(shí)還為體外診斷、生命科學(xué)研究、制藥等行業(yè)提供基于雜交瘤和噬菌體展示技術(shù)的抗體定制服務(wù)、以及試劑盒開發(fā)服務(wù)。公司座落于法國貝桑松，大約有25名專業(yè)人員。

Founded in 1986, Diaclone is widely recognized for its expertise in the fields of inflammation, oncology and immunology. The company offers best-in-class monoclonal antibodies, high quality ELISA and ELISpot kits as well as custom services - ranging from immunoassay kit development to new antibody discovery using hybridoma and phage display technologies - to a broad range of IVD, life science, and pharma customers. Diaclone employs a team of ca. 25 professionals in Besan?on, France. 


“成為IVD行業(yè)的首選獨(dú)立關(guān)鍵原料合作伙伴是Medix Biochemica的愿景，收購Diaclone是實(shí)現(xiàn)該愿景的重要一步。Diaclone的產(chǎn)品、包括幾個作為行業(yè)金標(biāo)準(zhǔn)的抗體，非常好地補(bǔ)充了Medix Biochemica的產(chǎn)品線。我們非常期待為全球客戶提供相關(guān)產(chǎn)品。另外，我們認(rèn)為Diaclone與Medix Biochemica的戰(zhàn)略和文化完美契合，也高度重視Diaclone的研發(fā)能力。我們期待在未來共同開發(fā)創(chuàng)新、高品質(zhì)的產(chǎn)品，以更好地支持我們的客戶”，Medix Biochemica首席執(zhí)行官Steve Ferguson說。

"The acquisition of Diaclone is an important step towards our vision to be the first-choice, independent raw material partner for the IVD industry. The portfolio of Diaclone, including several gold standard antibodies, complements the offering of Medix Biochemica very well, and we are excited about the opportunity to offer these products to our global customer base. In addition, we see an excellent strategic and cultural fit with Medix Biochemica, and we value Diaclone’s technical and scientific competence highly. We look forward to jointly developing innovative and high-quality products to support our customers even better in the future", says Steve Ferguson, CEO of Medix Biochemica. 


“經(jīng)過審慎評估，我們認(rèn)為現(xiàn)在是為支持Diaclone進(jìn)一步國際化增長而尋找新伙伴的最佳時(shí)機(jī)，我們深信Medix Biochemica以其全球服務(wù)能力，在質(zhì)量和研發(fā)方面巨大的投入，以及清晰的遠(yuǎn)見，是Diaclone新伙伴的最佳選擇”，Biotech Investissement集團(tuán)總裁Philippe Dulieu說。

"Following careful consideration, we concluded that it is the right time to find a new partner to support Diaclone's future international growth. We are convinced that Medix Biochemica with its comprehensive reach to IVD customers globally, strong focus on quality and R&D and clear long-term vision, is the optimal new partner for Diaclone", says Philippe Dulieu, President of Biotech Investissement Group.


如需更多信息，請聯(lián)系:

For more information:


Medix Biochemica中國商務(wù)團(tuán)隊(duì)

Commercial Team of Medix Biochemica China


Tel +86 21 6811 9180, 6811 9181, 6811 9105

Email: medixchina@medixbiochemica.com

關(guān)于Medix Biochemica


Medix Biochemica是IVD行業(yè)全球領(lǐng)先的供應(yīng)商。我們的使命是讓IVD合作伙伴能夠?yàn)閮|萬患者提供精準(zhǔn)的診斷結(jié)果。通過與Medix Biochemica合作 ，我們的客戶可以縮短產(chǎn)品開發(fā)周期，提升效率，保障產(chǎn)品質(zhì)量。對技術(shù)的深刻理解、對質(zhì)量不懈的堅(jiān)持和關(guān)注、以及超全面的相關(guān)產(chǎn)品線，是我們實(shí)現(xiàn)上述客戶價(jià)值的基石。

Medix Biochemica在全球約有200人左右的專業(yè)團(tuán)隊(duì)，總部位于芬蘭，通過在中國、歐洲、美國的團(tuán)隊(duì)， 我們?yōu)槿蚩蛻籼峁┓?wù)。


聯(lián)系我們

上海墨迪斯醫(yī)療技術(shù)有限公司 │ 上海市閔行浦江綠洲環(huán)路10號6幢(2號樓)11層

電話: +86 21 6811 9180, 6811 9181, 6811 9105 │ 傳真: +86 21 6811 9125

郵箱: medixchina@medixbiochemica.com │ 網(wǎng)址:  onb2b.cn